JP5416328B2 - 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 - Google Patents

血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 Download PDF

Info

Publication number
JP5416328B2
JP5416328B2 JP2004542620A JP2004542620A JP5416328B2 JP 5416328 B2 JP5416328 B2 JP 5416328B2 JP 2004542620 A JP2004542620 A JP 2004542620A JP 2004542620 A JP2004542620 A JP 2004542620A JP 5416328 B2 JP5416328 B2 JP 5416328B2
Authority
JP
Japan
Prior art keywords
gemcitabine
combination
pharmaceutically acceptable
cancer
warm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004542620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504723A5 (https=
JP2006504723A (ja
Inventor
バージ，アラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2006504723A publication Critical patent/JP2006504723A/ja
Publication of JP2006504723A5 publication Critical patent/JP2006504723A5/ja
Application granted granted Critical
Publication of JP5416328B2 publication Critical patent/JP5416328B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
JP2004542620A 2002-10-09 2003-10-06 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 Expired - Fee Related JP5416328B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0223380.7A GB0223380D0 (en) 2002-10-09 2002-10-09 Combination therapy
GB0223380.7 2002-10-09
PCT/GB2003/004334 WO2004032937A1 (en) 2002-10-09 2003-10-06 Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010287659A Division JP2011088921A (ja) 2002-10-09 2010-12-24 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用

Publications (3)

Publication Number Publication Date
JP2006504723A JP2006504723A (ja) 2006-02-09
JP2006504723A5 JP2006504723A5 (https=) 2006-11-24
JP5416328B2 true JP5416328B2 (ja) 2014-02-12

Family

ID=9945538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004542620A Expired - Fee Related JP5416328B2 (ja) 2002-10-09 2003-10-06 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用
JP2010287659A Pending JP2011088921A (ja) 2002-10-09 2010-12-24 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010287659A Pending JP2011088921A (ja) 2002-10-09 2010-12-24 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用

Country Status (22)

Country Link
US (2) US20060009418A1 (https=)
EP (1) EP1551409B1 (https=)
JP (2) JP5416328B2 (https=)
KR (1) KR101098061B1 (https=)
CN (1) CN100363004C (https=)
AT (1) ATE357236T1 (https=)
AU (1) AU2003269253B2 (https=)
BR (1) BR0315088A (https=)
CA (1) CA2501651C (https=)
CY (1) CY1106601T1 (https=)
DE (1) DE60312715T2 (https=)
DK (1) DK1551409T3 (https=)
ES (1) ES2282656T3 (https=)
GB (1) GB0223380D0 (https=)
IL (1) IL167633A (https=)
MX (1) MXPA05003595A (https=)
NO (1) NO330601B1 (https=)
NZ (1) NZ538999A (https=)
PT (1) PT1551409E (https=)
SI (1) SI1551409T1 (https=)
WO (1) WO2004032937A1 (https=)
ZA (1) ZA200502753B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011088921A (ja) * 2002-10-09 2011-05-06 Astrazeneca Ab 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301689B6 (cs) 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
JP4608215B2 (ja) 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ キナゾリン化合物
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
BRPI0612397A2 (pt) * 2005-07-06 2011-02-22 Astrazeneca Ab uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
EP2116246A1 (en) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
CN106727657A (zh) * 2016-12-27 2017-05-31 郑州郑先医药科技有限公司 一种治疗糖尿病的西药组合物及应用
CN106619688A (zh) * 2016-12-27 2017-05-10 郑州郑先医药科技有限公司 一种治疗糖尿病的药物组合物及应用
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CZ301689B6 (cs) * 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6953679B2 (en) * 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
KR20050056190A (ko) * 2002-08-09 2005-06-14 아스트라제네카 아베 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
BRPI0612397A2 (pt) * 2005-07-06 2011-02-22 Astrazeneca Ab uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
US20100212978A1 (en) * 2009-02-23 2010-08-26 Wen-Hung Huang Bicycle with two operation molds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011088921A (ja) * 2002-10-09 2011-05-06 Astrazeneca Ab 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用

Also Published As

Publication number Publication date
BR0315088A (pt) 2005-08-16
DE60312715D1 (de) 2007-05-03
NO20051575L (no) 2005-04-25
CA2501651A1 (en) 2004-04-22
ZA200502753B (en) 2006-03-29
ATE357236T1 (de) 2007-04-15
JP2011088921A (ja) 2011-05-06
KR20050055070A (ko) 2005-06-10
WO2004032937A1 (en) 2004-04-22
SI1551409T1 (sl) 2007-08-31
NZ538999A (en) 2008-02-29
IL167633A (en) 2013-03-24
AU2003269253A1 (en) 2004-05-04
HK1078771A1 (en) 2006-03-24
EP1551409B1 (en) 2007-03-21
US20060009418A1 (en) 2006-01-12
CN100363004C (zh) 2008-01-23
PT1551409E (pt) 2007-05-31
EP1551409A1 (en) 2005-07-13
US20100120708A1 (en) 2010-05-13
NO330601B1 (no) 2011-05-23
CN1703223A (zh) 2005-11-30
DK1551409T3 (da) 2007-06-11
ES2282656T3 (es) 2007-10-16
GB0223380D0 (en) 2002-11-13
KR101098061B1 (ko) 2011-12-26
DE60312715T2 (de) 2007-12-06
AU2003269253B2 (en) 2007-04-05
JP2006504723A (ja) 2006-02-09
MXPA05003595A (es) 2005-06-03
CA2501651C (en) 2011-02-15
CY1106601T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
JP5416328B2 (ja) 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用
WO2005004870A1 (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
EP1729808B1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11
AU2006264620B2 (en) Combination therapy of cancer with AZD2171 and gemcitabine
WO2005004871A1 (en) Combination therapy
JP2007530517A (ja) 組合せ療法
HK1078771B (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of cancer
HK1096023B (en) Combination therapy with azd2171 and 5-fu and/or cpt-11
CN101217966A (zh) 通过azd2171和吉西他滨对癌症的联合治疗
ZA200600186B (en) Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of deseases associated with angiogenesis and/or increased vascular permeability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130725

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130826

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131115

R150 Certificate of patent or registration of utility model

Ref document number: 5416328

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees